This HTML5 document contains 54 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n19http://linked.opendata.cz/resource/drugbank/drug/DB04845/identifier/chemspider/
n9http://linked.opendata.cz/resource/mesh/concept/
n7http://linked.opendata.cz/resource/drugbank/dosage/
n11http://linked.opendata.cz/resource/drugbank/drug/DB04845/identifier/wikipedia/
n12http://linked.opendata.cz/resource/drugbank/drug/DB04845/identifier/pharmgkb/
n6http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n20http://linked.opendata.cz/resource/drugbank/drug/DB04845/identifier/pubchem-compound/
n13http://linked.opendata.cz/resource/drugbank/patent/
n22http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n8http://linked.opendata.cz/ontology/mesh/
n18http://linked.opendata.cz/resource/drugbank/drug/DB04845/identifier/kegg-drug/
n21http://linked.opendata.cz/resource/drugbank/drug/DB04845/identifier/pubchem-substance/
n3http://linked.opendata.cz/ontology/drugbank/
n17http://linked.opendata.cz/resource/drugbank/drug/DB04845/identifier/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n16http://linked.opendata.cz/resource/atc/
n15http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB04845
rdf:type
n3:Drug
n3:description
Ixabepilone is an epothilone B analog developed by Bristol-Myers Squibb as a cancer drug. On October 16, 2007, the U.S. Food and Drug Administration approved ixabepilone for the treatment of aggressive metastatic or locally advanced breast cancer no longer responding to currently available chemotherapies. Ixabepilone is administered through injection, and will be marketed under the trade name Ixempra. [Wikipedia] Ixabepilone is a semisynthetic analogue of epothilone B. It has a lactone–lactam modification that minimizes susceptibility to esterase degradation.
n3:dosage
n7:271B5955-363D-11E5-9242-09173F13E4C5
n3:group
approved investigational
n3:halfLife
52 hours
n3:indication
Investigated for use/treatment in breast cancer, head and neck cancer, melanoma, lung cancer, lymphoma (non-hodgkin's), prostate cancer, renal cell carcinoma, and cancer/tumors (unspecified).
owl:sameAs
n6:DB04845 n22:DB04845
dcterms:title
Ixabepilone
adms:identifier
n11:Ixabepilone n12:PA165958343 n17:DB04845 n18:D04645 n19:4949236 n20:23305354 n21:99443224
n3:mechanismOfAction
Binding of Ixabepilone to beta-tubulins (e.g. beta-III tubulin) stabilizes microtubules. Microtubules are essential to cell division, and epothilones therefore stop cells from properly dividing. Like taxol, Ixabepilone binds to the αβ-tubulin heterodimer subunit. Once bound, the rate of αβ-tubulin dissociation decreases, thus stabilizing the microtubules.
n3:patent
n13:7312237 n13:6605599
n3:routeOfElimination
Mostly fecal and some renal.
n3:synonym
Azaepothilone B Aza-epothilone B
n3:proteinBinding
67-77%
n3:synthesisReference
Ismat Ullah, Gary Wiley, "Enteric coated bead comprising ixabepilone, and preparation and administration thereof." U.S. Patent US20060153917, issued July 13, 2006.
n8:hasConcept
n9:M0473543
n3:IUPAC-Name
n4:271B595A-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B5960-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B595F-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B595C-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B595D-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B595E-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B5958-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B5956-363D-11E5-9242-09173F13E4C5 n4:271B5959-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B5957-363D-11E5-9242-09173F13E4C5
n15:hasATCCode
n16:L01DC04
n3:H-Bond-Acceptor-Count
n4:271B5966-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B5967-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B5961-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B5962-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B5964-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B5963-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B5965-363D-11E5-9242-09173F13E4C5
n3:casRegistryNumber
219989-84-1
n3:Bioavailability
n4:271B596C-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B596E-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B596F-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B596B-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B596A-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B596D-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B595B-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B5968-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B5969-363D-11E5-9242-09173F13E4C5